FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Emerg Microbes Infect / A platform for the rapid screening of equine immunoglobins F...
Emerging microbes & infections2024; 13(1); 2396864; doi: 10.1080/22221751.2024.2396864

A platform for the rapid screening of equine immunoglobins F (ab)2 derived from single equine memory B cells able to cross-neutralize to influenza virus.

Abstract: Single B cells-based antibody platforms offer an effective approach for the discovery of useful antibodies for therapeutic or research purposes. Here we present a method for screening equine immunoglobins F(ab)2, which offers the potential advantage of reacting with multiple epitopes on the virus. Using equine influenza virus (EIV) as model, a hemagglutinin (HA) trimer was constructed to bait B cells in vaccinated horses. We screened 370 HA-specific B cells from 1 × 10 PBMCs and identified a diverse set of equine variable region gene sequences of heavy and light chains and then recombined with humanized Ig Fc. Recombinant equine Ig was then self-assembled in co-transfected 293 T cells, and subsequently optimized to obtain HA binding B-cell receptor (s). The recombinant antibodies exhibited a high binding affinity to the HA protein. Antibody H81 exhibited the highest cross neutralizing activities against EIV strains . Furthermore, it effectively protected EIV-challenged mice, resulting in significantly improved survival, reduced pulmonary inflammation and decreased viral titers. predication identified a functional region of H81 comprising 27 key amino acids cross the main circulating EIV strains. The 12 amino acid residues in this region with the highest binding affinities were screened. Notably, the predicted epitopes of H81 encompassed the documented equine HA receptor binding site, validating its cross-neutralization. In summary, a rapid platform was successfully established to investigate the profiling of equine antigen-recognizing receptors (BCRs) following infection. This platform has the potential to optimize the screening of virus-neutralizing antibodies and aid in vaccine design.
Get Full Text
Publication Date: 2024-09-27 PubMed ID: 39331815PubMed Central: PMC11441081DOI: 10.1080/22221751.2024.2396864Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

Overview

  • This research presents a rapid screening platform for identifying equine immunoglobulin F(ab)2 antibodies from single equine memory B cells that can broadly neutralize equine influenza virus (EIV).
  • The platform was used to discover antibodies with cross-protective capabilities, and one such antibody (H81) was shown to effectively protect mice from EIV infection.

Background and Significance

  • Single B cell-based antibody discovery platforms allow the isolation of specific antibodies with therapeutic or research potential.
  • Equine influenza virus (EIV) causes respiratory disease in horses, and broad neutralization antibodies would be valuable for treatment and vaccine development.
  • F(ab)2 fragments, which are antibody parts containing two antigen-binding sites without the Fc region, can bind multiple epitopes, potentially enhancing neutralization.

Methodology

  • Constructed an EIV hemagglutinin (HA) trimer protein used as bait to isolate HA-specific memory B cells from vaccinated horses.
  • Screened 370 HA-specific B cells isolated from peripheral blood mononuclear cells (PBMCs) of vaccinated horses.
  • Sequenced the variable regions of the heavy and light chains from these B cells to identify diverse equine antibody gene sequences.
  • Recombined these variable regions with humanized Ig Fc regions to create recombinant antibodies suitable for expression and functional testing.
  • Co-transfected recombinant antibodies into 293T cells for antibody expression and self-assembly.
  • Optimized the expressed F(ab)2 fragments to enhance the ability to bind HA protein, thus improving their affinity and neutralizing function.

Key Findings

  • The recombinant antibodies demonstrated high affinity binding to the influenza HA protein.
  • Among the antibodies, one named H81 exhibited the strongest cross-neutralizing activity against multiple EIV strains.
  • In vivo experiments with EIV-challenged mice showed that H81 antibody treatment:
    • Improved survival rates significantly.
    • Reduced lung inflammation caused by the virus.
    • Decreased viral load in lung tissues.
  • Epitope mapping and prediction identified a functional region in H81 composed of 27 critical amino acids conserved across major circulating EIV strains.
  • From this region, 12 amino acid residues with the highest binding affinities were further identified.
  • The predicted epitopes of H81 overlapped with the known receptor binding site on equine HA, explaining the broad neutralization ability.

Conclusions and Implications

  • This study successfully established a platform for rapid screening and characterization of equine antigen-specific B cell receptors post-infection or vaccination.
  • The platform enables the discovery of broadly neutralizing antibodies capable of cross-protecting against diverse virus strains.
  • The identified antibody H81 could serve as a model for therapeutic development against equine influenza infections.
  • Detailed epitope mapping of effective antibodies aids rational vaccine design by targeting conserved viral sites involved in receptor binding.
  • Overall, the approach enhances the ability to optimize antibody screening and vaccine strategies against equine influenza and potentially other viral diseases of horses.

Cite This Article

APA
Lin Y, Wang Y, Li H, Liu T, Zhang J, Guo X, Guo W, Wang Y, Liu X, Huang S, Liao H, Wang X. (2024). A platform for the rapid screening of equine immunoglobins F (ab)2 derived from single equine memory B cells able to cross-neutralize to influenza virus. Emerg Microbes Infect, 13(1), 2396864. https://doi.org/10.1080/22221751.2024.2396864

Publication

Emerging microbes & infections
ISSN: 2222-1751
NlmUniqueID: 101594885
Country: United States
Language: English
Volume: 13
Issue: 1
Pages: 2396864
PII: 2396864

Researcher Affiliations

Lin, Yuezhi
  • State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
Wang, Yayu
  • Zhuhai Trinomab Pharmaceutical Co., Ltd, Zhuhai, People's Republic of China.
Li, Hongxin
  • State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
Liu, Tong
  • Zhuhai Trinomab Pharmaceutical Co., Ltd, Zhuhai, People's Republic of China.
Zhang, Jiaqi
  • State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
Guo, Xing
  • State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
Guo, Wei
  • State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
  • Institute of Western Agriculture, the Chinese Academy of Agricultural sciences, Changji, People's Republic of China.
Wang, Yaoxin
  • State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
Liu, Xiangning
  • Clinical Research Platform for Interdiscipline of Stomatology, The First Affiliated Hospital of Jinan University, Guangzhou, People's Republic of China.
  • Department of Stomatology, College of Stomatology, Jinan University, Guangzhou, People's Republic of China.
Huang, Shaoli
  • The Hong Kong University of Science and Technology, School of Engineering, Hong Kong, People's Republic of China.
Liao, Huaxin
  • Zhuhai Trinomab Pharmaceutical Co., Ltd, Zhuhai, People's Republic of China.
Wang, XiaoJun
  • State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
  • Institute of Western Agriculture, the Chinese Academy of Agricultural sciences, Changji, People's Republic of China.

MeSH Terms

  • Animals
  • Horses
  • Orthomyxoviridae Infections / veterinary
  • Orthomyxoviridae Infections / prevention & control
  • Orthomyxoviridae Infections / immunology
  • Orthomyxoviridae Infections / virology
  • Mice
  • Antibodies, Viral / immunology
  • B-Lymphocytes / immunology
  • Antibodies, Neutralizing / immunology
  • Humans
  • Hemagglutinin Glycoproteins, Influenza Virus / immunology
  • Hemagglutinin Glycoproteins, Influenza Virus / genetics
  • Influenza A Virus, H3N8 Subtype / immunology
  • Influenza A Virus, H3N8 Subtype / genetics
  • Immunoglobulin Fab Fragments / immunology
  • Immunoglobulin Fab Fragments / genetics
  • Cross Reactions
  • HEK293 Cells
  • Influenza Vaccines / immunology
  • Immunologic Memory
  • Female
  • Epitopes / immunology

Conflict of Interest Statement

No potential conflict of interest was reported by the author(s).

References

This article includes 34 references
  1. Blackburne BP, Hay AJ, Goldstein RA. Changing selective pressure during antigenic changes in human influenza H3. PLoS Pathog 2008;4:e1000058.
    doi: 10.1371/journal.ppat.1000058pmc: PMC2323114pubmed: 18451985google scholar: lookup
  2. Braeye T, Catteau L, Brondeel R. Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021. Vaccine 2022;40:3027–3037.
    doi: 10.1016/j.vaccine.2022.04.025pmc: PMC9001203pubmed: 35459558google scholar: lookup
  3. Counts JA, Saunders KO. Guiding HIV-1 vaccine development with preclinical nonhuman primate research. Curr Opin HIV AIDS 2023;18:315–322.
    doi: 10.1097/COH.0000000000000819pmc: PMC10810179pubmed: 37712825google scholar: lookup
  4. Fonville JM, Wilks SH, James SL. Antibody landscapes after influenza virus infection or vaccination. Science 2014;346:996–1000.
    doi: 10.1126/science.1256427pmc: PMC4246172pubmed: 25414313google scholar: lookup
  5. Chiang HL, Liang KH, Lu RM. Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2. J Biomed Sci 2023;30:59.
    doi: 10.1186/s12929-023-00955-xpmc: PMC10388472pubmed: 37525188google scholar: lookup
  6. Frattari GS, Caskey M, Sogaard OS. Broadly neutralizing antibodies for HIV treatment and cure approaches. Curr Opin HIV AIDS 2023;18:157–163.
    doi: 10.1097/COH.0000000000000802pubmed: 37144579google scholar: lookup
  7. Sun X, Ma H, Wang X. Broadly neutralizing antibodies to combat influenza virus infection. Antiviral Res 2024;221:105785.
    doi: 10.1016/j.antiviral.2023.105785pubmed: 38145757google scholar: lookup
  8. Pedrioli A, Oxenius A. Single B cell technologies for monoclonal antibody discovery. Trends Immunol 2021;42:1143–1158.
    doi: 10.1016/j.it.2021.10.008pubmed: 34743921google scholar: lookup
  9. Saigusa R, Durant CP, Suryawanshi V. Single-cell antibody sequencing in atherosclerosis research. Methods Mol Biol 2022;2419:765–778.
    doi: 10.1007/978-1-0716-1924-7_46pmc: PMC10155217pubmed: 35238000google scholar: lookup
  10. Broketa M, Bruhns P. Single-cell technologies for the study of antibody-secreting cells. Front Immunol 2021;12:821729.
    doi: 10.3389/fimmu.2021.821729pmc: PMC8841722pubmed: 35173713google scholar: lookup
  11. Chai M, Guo Y, Yang L. A high-throughput single cell-based antibody discovery approach against the full-length SARS-CoV-2 spike protein suggests a lack of neutralizing antibodies targeting the highly conserved S2 domain. Brief Bioinform 2022;23:1–14.
    doi: 10.1093/bib/bbac070pubmed: 35362510google scholar: lookup
  12. Pan X, Zhou P, Fan T. Immunoglobulin fragment F(ab’)(2) against RBD potently neutralizes SARS-CoV-2 in vitro. Antiviral Res 2020;182:104868.
    doi: 10.1016/j.antiviral.2020.104868pmc: PMC7351055pubmed: 32659292google scholar: lookup
  13. Lim SA, Gramespacher JA, Pance K. Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2. MAbs 2021;13:1893426.
    doi: 10.1080/19420862.2021.1893426pmc: PMC7939556pubmed: 33666135google scholar: lookup
  14. Levy EM. The ability of horse serum to support an in vitro antibody response. J Immunol Methods 1980;36:181–183.
    doi: 10.1016/0022-1759(80)90042-3pubmed: 7000910google scholar: lookup
  15. Smith DJ, Lapedes AS, de Jong JC. Fouchier, mapping the antigenic and genetic evolution of influenza virus. Science 2004;305:371–376.
    doi: 10.1126/science.1097211pubmed: 15218094google scholar: lookup
  16. Mino S, Mojsiejczuk L, Guo W. Equine influenza virus in Asia: phylogeographic pattern and molecular features reveal circulation of an autochthonous lineage.. J Virol 2019;93.
    doi: 10.1128/JVI.00116-19pmc: PMC6580976pubmed: 31019053google scholar: lookup
  17. Whittle JR, Wheatley AK, Wu L. Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages.. J Virol 2014;88:4047–4057.
    doi: 10.1128/JVI.03422-13pmc: PMC3993745pubmed: 24501410google scholar: lookup
  18. Meier S, Guthe S, Kiefhaber T. Foldon, the natural trimerization domain of T4 fibritin, dissociates into a monomeric A-state form containing a stable beta-hairpin: atomic details of trimer dissociation and local beta-hairpin stability from residual dipolar couplings.. J Mol Biol 2004;344:1051–1069.
    doi: 10.1016/j.jmb.2004.09.079pubmed: 15544812google scholar: lookup
  19. Ford JE, Home WA, Gibson DM. Light chain isotype regulation in the horse. Characterization of Ig kappa genes.. J Immunol 1994;153:1099–1111.
    doi: 10.4049/jimmunol.153.3.1099pubmed: 8027543google scholar: lookup
  20. Liao HX, Levesque MC, Nagel A. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies.. J Virol Methods 2009;158:171–179.
    doi: 10.1016/j.jviromet.2009.02.014pmc: PMC2805188pubmed: 19428587google scholar: lookup
  21. Sun Y, Wang C, Wang Y. A comprehensive analysis of germline and expressed immunoglobulin repertoire in the horse.. Dev Comp Immunol 2010;34:1009–1020.
    doi: 10.1016/j.dci.2010.05.003pubmed: 20466019google scholar: lookup
  22. Remarque EJ, de Bruijn IA, Boersma WJ. Altered antibody response to influenza H1N1 vaccine in healthy elderly people as determined by HI, ELISA, and neutralization assay.. J Med Virol 1998;55:82–87.
    doi: 10.1002/(sici)1096-9071(199805)55:1<82::aid-jmv13>3.0.co;2-1pubmed: 9580890google scholar: lookup
  23. Wang Y, Wu C, Yu J. Structural basis of tetanus toxin neutralization by native human monoclonal antibodies.. Cell Rep 2021;35:109070.
    doi: 10.1016/j.celrep.2021.109070pubmed: 33951441google scholar: lookup
  24. Smith K, Garman L, Wrammert J. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen.. Nat Protoc 2009;4:372–384.
    doi: 10.1038/nprot.2009.3pmc: PMC2750034pubmed: 19247287google scholar: lookup
  25. Taguchi F, Hashimoto O, Matsuzaki T. A new neutralization method for influenza virus in cell culture.. Kitasato Arch Exp Med 1992;65:181–186.
    pubmed: 1344006
  26. Weis W, Brown JH, Cusack S. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid.. Nature 1988;333:426–431.
    doi: 10.1038/333426a0pubmed: 3374584google scholar: lookup
  27. Wrammert J, Smith K, Miller J. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus.. Nature 2008;453:667–671.
    doi: 10.1038/nature06890pmc: PMC2515609pubmed: 18449194google scholar: lookup
  28. Horns F, Dekker CL, Quake SR. Memory B cell activation, broad anti-influenza antibodies, and bystander activation revealed by single-cell transcriptomics.. Cell Rep 2020;30:905–913.e6.
    doi: 10.1016/j.celrep.2019.12.063pmc: PMC7891556pubmed: 31968262google scholar: lookup
  29. Altman MO, Angeletti D, Yewdell JW. Antibody immunodominance: the key to understanding influenza virus antigenic drift.. Viral Immunol 2018;31:142–149.
    doi: 10.1089/vim.2017.0129pmc: PMC5863095pubmed: 29356618google scholar: lookup
  30. Sandbulte MR, Westgeest KB, Gao J. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses.. Proc Natl Acad Sci USA 2011;108:20748–20753.
    doi: 10.1073/pnas.1113801108pmc: PMC3251064pubmed: 22143798google scholar: lookup
  31. Reid AH, Taubenberger JK, Fanning TG. Evidence of an absence: the genetic origins of the 1918 pandemic influenza virus. Nat Rev Microbiol 2004;2:909–914.
    doi: 10.1038/nrmicro1027pmc: PMC7097663pubmed: 15494747google scholar: lookup
  32. Fleishman SJ, Whitehead TA, Ekiert DC. Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science 2011;332:816–821.
    doi: 10.1126/science.1202617pmc: PMC3164876pubmed: 21566186google scholar: lookup
  33. Musnier A, Bourquard T, Vallet A. A new in silico antibody similarity measure both identifies large sets of epitope binders with distinct CDRs and accurately predicts off-target reactivity. Int J Mol Sci 2022;23.
    doi: 10.3390/ijms23179765pmc: PMC9456297pubmed: 36077163google scholar: lookup
  34. Nabel GJ, Fauci AS. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med 2010;16:1389–1391.
    doi: 10.1038/nm1210-1389pubmed: 21135852google scholar: lookup

Citations

This article has been cited 3 times.
  1. Kökkaya S, Göksu AG, Sözdutmaz İ, Toy MA, Berber E. Monoclonal antibodies in veterinary antiviral immunotherapy: technologies, applications and challenges. Vet Res Commun 2025 Oct 22;49(6):366.
    doi: 10.1007/s11259-025-10912-8pubmed: 41123752google scholar: lookup
  2. Yu L, Li F, Zou X, Xu L, Zhao J, Li Y, Peng G, Xia Y, Zhao Q, Zhu Y. Development and Application of Mouse-Derived CD2v Monoclonal Antibodies Against African Swine Fever Virus from Single B Cells. Viruses 2025 Aug 15;17(8).
    doi: 10.3390/v17081123pubmed: 40872837google scholar: lookup
  3. Firdausy LW, Fikri F, Wicaksono AP, Çalışkan H, Purnama MTE. Global prevalence and risk factors of equine infectious anemia: A systematic review and meta-analysis. Vet World 2025 Jun;18(6):1440-1451.
    doi: 10.14202/vetworld.2025.1440-1451pubmed: 40689174google scholar: lookup
Subscribe to our newsletter
Join 99,093 horse owners like you who receive our email updates on horse health and nutrition.